Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.

Hermine I BrunnerNicolino RupertoAthimalaipet V RamananGerd HorneffKirsten MindenInmaculada Calvo PenadesEkaterina AlexeevaGavin ClearySara M SternIsabelle Kone-PautMaría Del Rocío Maldonado VelázquezC Egla RabinovichAgustin RemesalClovis Artur SilvaIrina NikishinaMauro ZucchettoLaura BrockwellOliver GordonSandra NagelFabrizio De Benedettinull null

Published in: Rheumatology (Oxford, England) (2024)

Patients with pJIA or sJIA experienced long-term disease control with SC-TCZ treatment. Long-term safety was consistent with the known tocilizumab safety profile.

Keyphrases

juvenile idiopathic arthritis
clinical trial
disease activity
rheumatoid arthritis
systemic lupus erythematosus
randomized controlled trial
combination therapy
smoking cessation
double blind